Presentations

Exploration of alternative regorafenib regimens to manage hand – foot skin reaction

Ploeger B., Hoefman S., Ruppert M., Vis P., Zisowsky J., Grothey A., Cutsem E., Dochy E.v., Cleton A. Exploration of alternative regorafenib regimens to manage hand – foot skin reaction. European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer, 2019. [Link to publication]

Application of population PK/PD modeling and simulation to inform the design of a dose-finding study in patients with schizophrenia

Berkhout J., Post T.M., Xu L., Zhang L., Wendland J., Faessel H., Vakilynejad M. Application of population PK/PD modeling and simulation to inform the design of a dose-finding study in patients with schizophrenia. PAGE, 2019.  [Link to publication]

A mechanism-based population K-PD model for long-term testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy

Dejongh J. Ahsman M.& Snelder N. A mechanism-based population K-PD model for long-term testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy. PAGE 2019/ IATDMCTS 2019. [Link to publication]

Integrate QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist

Bosch R., Petrone M.,Hoefman S., Arends R., Vicini P., Snelder N. Integrate QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist. WCDT 2019. [Link to publication]

Application of a MK-3682 minimal PBPK-PD model

Berg P.v.d., Post T.M., Gao W., Miller R., Kesisoglou F., Arrington L., Rizk M.L. Application of a MK-3682 minimal PBPK-PD model to explain discrepancy between enhanced efficacy and PK in the presence of itraconazole. ACoP9, 2018.

A project-centric R / Shiny run management tool for nlmixr

Hooijmaijers R., Fidler M., Schoemaker R., Trame M.N., Wang W., Wilkins J., Post T.M. ShinyMixR : A project-centric R / Shiny run management tool for nlmixr. PAGE, 2018. [Link to publication]

An HCV nucleoside inhibitor MK-3682 minimal PBPK-PD model

Berg P.v.d., Post T.M., Gao W., Miller R., Kesisoglou F., Arrington L., Rizk M.L. An HCV nucleoside inhibitor MK-3682 minimal PBPK-PD model for application in hypothesis generation regarding metabolic pathways and perturbations under various conditions. PAGE, 2018. [Link to publication]

A novel integrated QSP model of in vivo human glucose regulation

Bosch R., Petrone M., Vicini P., Snelder N. A novel integrated QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist. PAGE, 2018. [Link to publication]

35 years of modelling and simulation

Jongh J. de. 35 years of modelling and simulation as robust tools in drug development From terminal half-life to quantitative and translational systems pharmacology. 22nd MDO / 33rd JSSX, 2018.

Development of a mathematical model to elucidate the cross- linking of GSK1995057 and ADAs and binding to TNFR1 receptor

Steeg T.J.v., Keunecke A., Fairman D. Development of a mathematical model to elucidate the cross- linking of GSK1995057 and ADAs and binding to TNFR1 receptor – filling the gap between hypothesis and reality. PAGE, 2018. [Link to publication]